Clinical Trials Logo

Conjunctivitis, Allergic clinical trials

View clinical trials related to Conjunctivitis, Allergic.

Filter by:

NCT ID: NCT01438827 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Avanz Phleum Pratense Maintenance Dose

Start date: September 2011
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.

NCT ID: NCT01438463 Completed - Allergic Rhinitis Clinical Trials

PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis

Start date: September 2011
Phase: Phase 2
Study type: Interventional

The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety. For this purpose 5 groups of 50 patients, suffering from rhinitis or rhinoconjunctivitis due to House Dust Mite Allergy will be treated during 1 year. Before start, after 6 months of treatment and at the end of the study patients will be subjected to a nasal provocation test.

NCT ID: NCT01437982 Completed - Inflammation Clinical Trials

A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

Start date: August 5, 2010
Phase: Phase 4
Study type: Interventional

The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice

NCT ID: NCT01435460 Completed - Clinical trials for Seasonal Allergic Conjunctivitis

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

Start date: August 2010
Phase: Phase 3
Study type: Interventional

This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal Allergic Conjunctivitis (SAC).

NCT ID: NCT01363713 Completed - Clinical trials for Allergic Conjunctivitis

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Start date: n/a
Phase: Phase 3
Study type: Interventional

Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.

NCT ID: NCT01363700 Completed - Clinical trials for Allergic Conjunctivitis

Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.

NCT ID: NCT01346371 Completed - Clinical trials for Allergic Conjunctivitis

The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer

Start date: May 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.

NCT ID: NCT01344083 Completed - Clinical trials for Seasonal Allergic Conjunctivitis

Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

Start date: April 2011
Phase: Phase 2
Study type: Interventional

The aim of this study is to compare the efficacy and the safety of T1210 versus Olopatadine eye drops in the topical treatment of seasonal allergic conjunctivitis.

NCT ID: NCT01342601 Completed - Clinical trials for Seasonal Allergic Rhinitis

Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents

Start date: April 2011
Phase: N/A
Study type: Interventional

Ectoin acts on membranes by forming an Ectoin-Hydro-Complex therewith providing a protection against external agents like aeroallergens. The effects of Ectoin containing nasal spray and eye drops have already been demonstrated in several studies with adult Seasonal Allergic Rhinitis (SAR) patients and it was shown that they can effectively reduce symptoms of allergic rhinitis without resulting in any significant adverse events. The aim of this clinical investigation is to demonstrate the safety, tolerability and efficacy of Ectoin Nasal Spray and Ectoin Eye Drops in pediatric and adolescent SAR patients. It is assumed that Ectoin containing products show an excellent safety profile and very good tolerability together with a potent efficacy in the treatment of SAR.

NCT ID: NCT01339507 Completed - Clinical trials for Allergic Conjunctivitis

A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft

Start date: April 2011
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the comfort of BEPREVE compared to LASTACAFT after instillation.